Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03579446 · ClinicalTrials.gov registry record · Early Phase 1
Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer
A Early Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 43
- Enrollment target
NCT03579446: Clinical Trial Early Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT03579446 is a Early Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03579446, a Early Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
This early phase I trial studies how well levorphanol works as a second line opioid in reducing pain in patients with cancer that may have spread to other places in the body. Levorphanol may work better in controlling cancer pain.
Interventions
- DRUG Oxycodone
- DRUG Hydromorphone
- DRUG Morphine
- DRUG Hydrocodone
- DRUG Levorphanol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2018-11-29 |
| Est. Completion | 2023-06-15 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03579446
The ClinicalTrials.gov registry entry for NCT03579446 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Oxycodone is the first listed.
NCT03579446 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03579446 about?
NCT03579446 is a clinical study titled "Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer". This early phase I trial studies how well levorphanol works as a second line opioid in reducing pain in patients with cancer that may have spread to other places in the body. Levorphanol may work better in controlling cancer pain.
What is the current status of trial NCT03579446?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 43 participants. The study started on 2018-11-29. Estimated completion is 2023-06-15.
What interventions are being tested in trial NCT03579446?
The interventions under investigation include: Oxycodone (DRUG), Hydromorphone (DRUG), Morphine (DRUG), Hydrocodone (DRUG), Levorphanol (DRUG).
Who is sponsoring clinical trial NCT03579446?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.